FDA Clearance for Rapid Detection of Antibiotic Resistant Gram Positives
Dade Behring Inc. has received clearance from the FDA for use of its MicroScan® Synergies plus Gram-positive panels. The new technology used in the panels allows for rapid two-hour identification of bacteria and same-day test results for detecting certain antibiotic-resistant bacteria that cause serious health threats in a hospital environment. Some of the antibiotic-resistant bacteria that may be identified on the same-day tested are:
With the addition of Synergies plus Gram-positive panels, the Company now offers automated solutions for rapid identification and same-day detection of antibiotic-resistant bacteria, both for Gram-positive and Gram-negative bacteria. This is especially important as more strains of bacteria become resistant to antibiotics. For example, in 1971, the Centers for Disease Control and Prevention (CDC) reported only two percent of staphylococcus infections as resistant to the antibiotic methicillin. This number increased to 22 percent in 1995 and nearly 63 percent in 2004, resulting in an increase in the use of the antibiotic vancomycin[1-3]. The growing dependency on vancomycin led to the emergence of vancomycin-resistant S. aureus and enterococcus infections, posing a threat to health care environments and demonstrating a global trend that is expected to continue[1-3].
Source: Dade Behring, Inc. View latest company information
Posted: October 18, 2007
[will open your email client]